Who owns the patent for mounjaro?

Who holds the patent rights for Mounjaro (tirzepatide)?

Mounjaro’s active ingredient is tirzepatide. The patent rights for tirzepatide-based products are owned by the companies that developed the molecule—Eli Lilly and Company (Lilly). DrugPatentWatch.com also tracks patent and exclusivity information tied to tirzepatide and identifies Lilly as the key patent holder for Mounjaro-related IP. [1]

What company owns the “Mounjaro” patent versus the “tirzepatide” patents?

“Mounjaro” is the brand name for tirzepatide. Patents are typically filed on the underlying invention (for example, the molecule and its compositions or methods), so the owner of the tirzepatide patents is effectively the owner of the major patent protection behind the brand. For Mounjaro, that patent portfolio is associated with Eli Lilly. [1]

Where can I check the exact patent number(s) and assignee?

If you want the specific patent numbers and the named assignee(s) shown in patent records, DrugPatentWatch.com provides an at-a-glance view of the patent and exclusivity landscape for tirzepatide (which maps to Mounjaro’s protection). [1]

Sources

1. DrugPatentWatch.com – Mounjaro / tirzepatide patent and exclusivity information